23andMe Investor Day Presentation Deck

CD96 is Part of the Genetically-validated CD226 Axis and is Progressing in Clinical Development • The 23andMe immuno-oncology signature has highlighted the importance of the CD226 pathway which includes CD96 and TIGIT • Combining components of the CD226 pathway may be more efficacious than inhibiting single components, but will require complex clinical trials o GSK has the relevant agents to target the CD226 axis • The Phase 1 clinical trial with GSK'608 (anti-CD96) and dostarlimab is ongoing (conducted by GSK) o Data is expected in 2022 Copyright © 2022 23andMe, Inc. 23andMe® 48

View entire presentation